Skip to content

Depreciation at other companies

Gilead Sciences logo
Gilead SciencesGILD
Vor Biopharma logo
Vor BiopharmaVOR
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$907.23M+54.1%
Enterprise value$898.76M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Reported directly by Sana Biotechnology in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's depreciation?
Sana Biotechnology (SANA) reported depreciation of $2.39M in Q1 2026.
How has Sana Biotechnology's depreciation changed year-over-year?
Sana Biotechnology's depreciation decreased by 34.5% year-over-year, from $3.65M to $2.39M.